Valneva Austria GmbH

VLA1553 Chikungunya Vaccine Shows Durable Antibody Response at Two Years

8 months ago

• A phase 3b trial of VLA1553 showed that chikungunya virus-neutralizing antibodies persisted for up to two years post-vaccination. • Seroprotection rates remained high, at or above 97% at one year and 96.8% at two years, across all age groups studied. • The study found no long-term safety concerns related to VLA1553, with serious adverse events deemed unrelated to the vaccine. • These findings support VLA1553's potential for active immunization in individuals living in or traveling to chikungunya-endemic areas.